Small molecule inhibitor of HIV-1 nuclear import suppresses HIV-1 replication in human lymphoid tissue ex vivo: a potential addition to current anti-HIV drug repertoire.
Antiviral Res
; 47(2): 89-95, 2000 Aug.
Article
en En
| MEDLINE
| ID: mdl-10996396
ABSTRACT
Despite recent progress in anti-HIV therapy, which has to do mainly with introduction of protease inhibitors into clinical practice, drug toxicity and emergence of drug-resistant isolates during the long-term treatment of the patients necessitates search for new drugs that can be added to currently used components of a multi-drug cocktail in highly active anti-retroviral therapy (HAART). Recently, we described a class of arylene bis(methylketone) compounds that inhibit nuclear import of HIV-1 pre-integration complexes and suppress viral replication in macrophages and PBMC in vitro. In this report, we demonstrate that one of these compounds, CNI-H1194, inhibited HIV-1 replication in primary lymphoid tissue ex vivo. The compound did not antagonize the activity of currently used anti-HIV drugs that inhibit viral reverse transcriptase or protease. These results suggest that arylene bis(methylketone) compounds might be a valuable addition to HAART.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Pirimidinas
/
Tonsila Palatina
/
VIH-1
/
Compuestos de Anilina
Límite:
Humans
Idioma:
En
Revista:
Antiviral Res
Año:
2000
Tipo del documento:
Article
País de afiliación:
Estados Unidos